Related references
Note: Only part of the references are listed.Understanding and overcoming trade-offs between antibody affinity, specificity, stability and solubility
Lilia A. Rabia et al.
BIOCHEMICAL ENGINEERING JOURNAL (2018)
Establishing in vitro in vivo correlations to screen monoclonal antibodies for physicochemical properties related to favorable human pharmacokinetics
Lindsay B. Avery et al.
MABS (2018)
Albumin-binding domain from Streptococcus zooepidemicus protein Zag as a novel strategy to improve the half-life of therapeutic proteins
Catia Cantante et al.
JOURNAL OF BIOTECHNOLOGY (2017)
Distribution of FcRn Across Species and Tissues
Sari Latvala et al.
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY (2017)
Strategies and challenges for the next generation of antibody drug conjugates
Alain Beck et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants
Qing Zhu et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Engineered clearing agents for the selective depletion of antigen-specific antibodies
Siva Charan Devanaboyina et al.
NATURE COMMUNICATIONS (2017)
Structural analysis of Fc/FcR complexes: a blueprint for antibody design
Jose M. M. Caaveiro et al.
IMMUNOLOGICAL REVIEWS (2015)
The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity
Yasmina Noubia Abdiche et al.
MABS (2015)
Fc fusion as a platform technology: potential for modulating immunogenicity
Ditza Levin et al.
TRENDS IN BIOTECHNOLOGY (2015)
Targeting the Fc receptor in autoimmune disease
Xinrui Li et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2014)
Use of Fc-Engineered Antibodies as Clearing Agents to Increase Contrast During PET
Rafal Swiercz et al.
JOURNAL OF NUCLEAR MEDICINE (2014)
A novel approach to investigate the effect of methionine oxidation on pharmacokinetic properties of therapeutic antibodies
Jan Stracke et al.
MABS (2014)
Binding structures and energies of the human neonatal Fc receptor with human Fc and its mutants by molecular modeling and dynamics simulations
Xiaoqin Huang et al.
MOLECULAR BIOSYSTEMS (2013)
Engineering neonatal Fc receptor-mediated recycling and transcytosis in recombinant proteins by short terminal peptide extensions
Jonathan T. Sockolosky et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Hck Tyrosine Kinase Regulates TLR4-Induced TNF and IL-6 Production via AP-1
Maria J. Smolinska et al.
JOURNAL OF IMMUNOLOGY (2011)
Increased rheumatoid factor interference observed during immunogenicity assessment of an Fc-engineered therapeutic antibody
James Araujo et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2011)
Neonatal Fc receptor and IgG-based therapeutics
Timothy T. Kuo et al.
MABS (2011)
The impact of glycosylation on monoclonal antibody conformation and stability
Kai Zheng et al.
MABS (2011)
Effects of Charge on Antibody Tissue Distribution and Pharmacokinetics
C. Andrew Boswell et al.
BIOCONJUGATE CHEMISTRY (2010)
Identification of glutamate 344 as the catalytic residue in the active site of pig heart CoA transferase
Jean-Christophe Rochet et al.
PROTEIN SCIENCE (2010)
Functional and structural characterisation of human colostrum free secretory component
Adel Almogren et al.
MOLECULAR IMMUNOLOGY (2009)
Reduction of IgG in nonhuman primates by a peptide antagonist of the neonatal Fc receptor FcRn
Adam R. Mezo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Neonatal FcR expression in bone marrow-derived cells functions to protect serum IgG from catabolism
Shreeram Akilesh et al.
JOURNAL OF IMMUNOLOGY (2007)
An automated decision-tree approach to predicting protein interaction hot spots
Steven J. Darnell et al.
PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS (2007)
Monoclonal antibody clearance -: Impact of modulating the interaction of IgG with the neonatal Fc receptor
Amita Datta-Mannan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Humanized IgG(1) variants with differential binding properties to the neonatal Fc receptor: relationship to pharmacokinetics in mice and primates
Amita Datta-Mannan et al.
DRUG METABOLISM AND DISPOSITION (2007)
Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies
Carlos Vaccaro et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn)
William F. Dall'Acqua et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Albumin binding to FcRn: Distinct from the FcRn-IgG interaction
C Chaudhury et al.
BIOCHEMISTRY (2006)
Bruton's tyrosine kinase is required for TLR2 and TLR4-Induced TNF, but not IL-6, production
Nicole J. Horwood et al.
JOURNAL OF IMMUNOLOGY (2006)
Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels
C Vaccaro et al.
NATURE BIOTECHNOLOGY (2005)
The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs
DC Roopenian et al.
JOURNAL OF IMMUNOLOGY (2003)
Expression of H-ficolin/Hakata antigen, mannose-binding lectin-associated serine protease (MASP)-1 and MASP-3 by human glioma cell line T98G
M Kuraya et al.
INTERNATIONAL IMMUNOLOGY (2003)
High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR
RL Shields et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Share Paper
